Manufacturing concerns licked for pain drug Remoxy; PharmaCell to make Dendreon's Provenge in EU;

@EricPFierce: Samsung, which has worked on a biosimilar of Rituxan, has a new deal to make biologics for Roche. Article | Follow @EricPFierce

> DURECT said that now that the FDA's concerns over the manufacture of its tamper-resistant oxycodone capsules Remoxy have been overcome, Pfizer ($PFE) will continue with its development. Release

> In the second installment of reports being released at the CPhI trade show in Frankfurt, Germany, this week, experts find that drugmakers are developing deeper ties with contract manufacturers with high quality standards. Report (PDF)

> Nanotherapeutics has opened a development and manufacturing facility in Copeland Park, FL, which will be used to fulfill its part of a Department of Defense contract for developing and manufacturing vaccines for the military. Story

> The FDA says that Specialty Medicine Compounding Pharmacy of South Lyon, MI, is recalling both human and veterinary drugs shipped in that state after particulate matter was found floating in a sterile product from the same lot. Release

> The FDA says by the end of the year it will no longer approve the Combivent Inhalation Aerosol and the Maxair Autohaler, the last two inhalers on the market that still use chlorofluorocarbons (CFCs). Release

> Dendreon ($DNDN) has hired CMO PharmaCell to produce its prostate cancer drug Provenge in Europe. Release

> The American Civil Liberties Union Wednesday filed a lawsuit against Missouri prison officials to force the state to say which compounding pharmacies are supplying its lethal execution drugs, as well as to identify other members of its death row execution team. Story

And Finally... A drug manufacturing plant in Buffalo, NC, that was owned by Westwood Pharmaceuticals and then Bristol-Myers Squibb ($BMY) is being razed and the site will be used for college apartments. Story